Journals / MN Oftalmoloji / 2010 / Cilt: 17 - Sayı: 4

Subconjunctival bevacizumab injection in the treatment of corneal neovascularization

Kornea neovaskülarizasyonunda subkonjunktival bevacizumab enjeksiyonu

Pages
197–201
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Such treatment may be a short-term alternative in the management of corneal neovascularization.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To evaluate the safety and efficacy of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
📊
Key Findings & Data:Material and Method: Fifteen eyes of 12 patients with stable corneal neovascularization were included into this prospective study.
💡
Conclusion & Impact:Such treatment may be a short-term alternative in the management of corneal neovascularization.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kök hücreler · İleriye dönük çalışma · Vasküler endoteliyal büyüme faktör A

Abstract

Aim: To evaluate the safety and efficacy of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Material and Method: Fifteen eyes of 12 patients with stable corneal neovascularization were included into this prospective study. Following a detailed eye examination, digital photographs were taken and all patient eyes received subconjunctival injection of bevacizumab at every month. The area of corneal neovascularization was graded with slit lamp and with digital photograph analysis before injection and at monthly follow-up visits. Results: Nine eyes were treated with 2.5 mg/0.1 ml of bevacizumab, six eyes were treated with 5 mg/0.2 ml of bevacizumab subconjunctivally. Four eyes with no change in corneal vascularization after 3 injections of 2.5 mg/0.1 ml bevacizumab received 3 more injections of 5 mg/0.2 ml bevacizumab. The extent of neovascularization decreased from 8.1±3.1 clock hours pre-injection to 5.5±2.4 clock hours post-injection. No ocular or systemic adverse events were observed. Conclusions: Subconjunctival injections of bevacizumab is well tolerated and can provide partial regression of corneal neovascularization in the short term. Such treatment may be a short-term alternative in the management of corneal neovascularization.

Özet

Amaç: Kornea neovaskülarizasyonu olan olgularda subkonjonktival bevacizumab (Avas - tin,Genentech, ABD) enjeksiyonunun etkinliği ve güvenirliliğinin değerlendirilmesi. Gereç ve Yöntem: Ankara Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı Kor - nea birimine başvuran çeşitli nedenlerle kornea neovaskülarizasyonu gelişmiş 12 olgunun 15 gözü prospektif olarak çalışmaya alındı. Tüm olgularda tam oftalmolojik muayeneyi takiben ön segment fotoğrafı çekildi ve ayda bir subkonjunktival bevacizumab enjeksiyonu yapıldı. Ol - gu lar aylık biyomikroskopi muayenesi ve ön segment fotoğrafı ile neovaskülarizasyon alanında ge rileme açısından değerlendirildi. Bulgular: Subkonjunktival bevacizumab enjeksiyonu 9 göze 2,5 mg/0,1 ml, 6 göze 5 mg/ 0,2 ml olarak uygulandı. Üç defa 2,5 mg/0,1 ml enjeksiyon yapılan dört gözde etki izlenmemesi ne deniyle doz artırılarak enjeksiyon 5 mg/0,2 ml dozunda üç kez uygulandı. Kornea damarlan - ma sının enjeksiyon öncesi ortalama 8,1±3,1 saat kadranından, enjeksiyon sonrası ortalama 5,5±2,4 saat kadranına gerilediği görüldü. Neovaskülarizasyon alanındaki ortalama azalmanın %21,6 olduğu belirlendi. Hiçbir olguda enjeksiyona bağlı belirgin bir yan etki izlenmedi. Sonuç: Subkonjunktival bevacizumab enjeksiyonu, belirgin bir yan etkiye yol açmaksızın kısa süreli takipte kornea neovaskülarizasyonunda kısmi gerileme sağlayabilir ve bu nedenle kornea neovaskülarizasyonunun kısa dönem tedavisinde bir alternatif olabilir.

🔖

Cite This Article

GÜLTEKİN, B. P., GÜNDÜZ, Ö. U., KANPOLAT, A. (2010). Subconjunctival bevacizumab injection in the treatment of corneal neovascularization. MN Oftalmoloji, Cilt: 17 - Sayı: 4, 197–201. https://ajindex.com/articles/297047

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242-9
  2. Han YS, Lee JE, Jung JW, Lee JS. Inhibitory effects of bevacizumab on angiogenesis and corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:541-8
  3. Kim TI, Kim SW, Kim S, Kim T, Kim EK. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea 2008;27:349-52
  4. Hosseini H, Nejabat M, Mehryar M, Yazdchi T, Sedaghat A, Noori F. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007;35:745-8
  5. Manzano R, Peyman G, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol 2007;91:804-7
  6. Lee SH, Leem HS, Jeong SM, Lee K. Bevacizumab accelerates corneal wound healing by inhibiting TGF-β2 expression in alkali-burned mouse cornea. BMB reports 2009;42:800-5
  7. Saravia M, Zapata G, Ferraiolo P, Racca L, Berra A. Anti- VEGF monoclonal antibody-induced regression of corneal neovascularization and inflammation in a rabbit model of herpetic stromal keratitis. Graefes Arch Clin Exp Ophthalmol 2009;247:1409-16
  8. Bahar I, Kaiserman I, McAllum P, Rootman D, Slomovic A. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008;27:142-7
  9. Zaki AA, Farid SF. Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 2010;88:868-71
  10. Erdurmuş M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthal - mol 2007;245:1577-9
  11. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008;27,992-5
  12. You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009;87:653-8
  13. Ahmed A, Berati H, Nalan A, Aylin S. Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Exp Ophthalmol 2009;37:730-6
  14. Kim WJ, Jeong HO, Chung SK. The effect of bevacizumab on corneal neovascularization in rabbits. Korean J Ophthalmol 2010;24:230-6
  15. Dastjerdi MH, Saban DR, Okanobo A, et al. Effect of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010;51:2411-7
  16. Hürmeriç V, Erdurman FC, Mumcuoğlu T, ve ark. Deneysel kor nea neovaskülarizasyonu mode